FDA Approves Giredestrant for ESR1-Mutated Breast Cancer
The oral estrogen receptor antagonist, paired with everolimus, is cleared for adults with ER-positive, HER2-negative advanced breast cancer.
Updated on Nov. 16, 2026 in Cancer

The FDA approved giredestrant (Wilserdly, Genentech, Inc.) with everolimus on November 16, 2026, for adults with ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer. The agency also authorized the FoundationOne Liquid CDx assay as a companion diagnostic to identify eligible patients.
Why it matters
The approval covers patients whose disease recurred during or after endocrine-based adjuvant therapy or progressed on at least one endocrine-based metastatic regimen, a population with limited options. The companion diagnostic gives clinicians a defined way to identify ESR1-mutated tumors for treatment.
The evERA Breast Cancer trial enrolled 373 adults, including 207 with ESR1 mutations, and randomized them 1:1 to giredestrant with everolimus or physician's choice endocrine therapy. The reported comparisons do not yet address overall survival, and the extraction does not specify longer-term outcomes.
The players
Genentech, Inc.
Genentech is a biotechnology company and a member of the Roche Group, known for developing oncology therapies, and it markets giredestrant as Wilserdly.
U.S. Food and Drug Administration
The FDA is the federal agency responsible for approving drugs and authorizing diagnostic devices for sale in the United States.
The details
Patients in both trial arms received everolimus 10 mg once daily, and pre- and peri-menopausal women received a GnRH agonist for ovarian function suppression. Giredestrant is taken orally at 30 mg once daily, and the companion diagnostic FoundationOne Liquid CDx was authorized alongside the drug.
Timeline
November 16, 2026: FDA approval of giredestrant with everolimus, about four weeks ahead of the agency's goal date.
Health Landscape
The approval extends the oral, ESR1-targeted approach that began with elacestrant's 2023 FDA approval into a combination regimen with everolimus. It adds a companion diagnostic framework that ties treatment eligibility to tumor ESR1 mutation status.
Patients with ESR1-mutated, ER-positive, HER2-negative advanced breast cancer who have progressed on endocrine therapy may now have an oral combination option. Eligibility depends on a companion diagnostic test confirming the ESR1 mutation.
The takeaway
Patients whose breast cancer carries an ESR1 mutation should ask their oncologist whether mutation testing has been done, since it determines eligibility for this oral combination therapy.
Further reading
For more on treatment advances, see the Cancer section.






